National Accreditation Board for Testing and Calibration Laboratories

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 1 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
Permanent Facility				
1	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Friability	STP/TB24/004, ISSUE DT:17/05/2019
2	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	2,6-Dimethylaniline	STP/BPC/303, ISSUE DT:24/07/2020
3	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Assay (By HPLC) Bupivacaine HCL 5mg	STP/BPC/303, ISSUE DT:24/07/2020
4	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Assay (By HPLC) Methyl Paraben IP 0.8mg	STP/BPC/303, ISSUE DT:24/07/2020
5	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Description	STP/BPC/303, ISSUE DT:24/07/2020
6	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Identification	STP/BPC/303, ISSUE DT:24/07/2020
7	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Particulate matter by visual inspection	STP/BPC/303, ISSUE DT:24/07/2020
8	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride Injection	Related substances	STP/BPC/303, ISSUE DT:24/07/2020
9	CHEMICAL- DRUGS & PHARMACEUTICALS	Amlodipine Besylate 5 mg & Atenolol 50 mg Tablet	Description	STP/TB26/025, ISSUE DT:13/09/2020
10	CHEMICAL- DRUGS & PHARMACEUTICALS	Amlodipine Besylate 5 mg & Atenolol 50 mg Tablet	Identification(By UV)	STP/TB26/025, ISSUE DT:13/09/2020
11	CHEMICAL- DRUGS & PHARMACEUTICALS	Amlodipine Besylate 5 mg & Atenolol 50 mg Tablet	Uniformity of content	STP/TB26/025, ISSUE DT:13/09/2020
12	CHEMICAL- DRUGS & PHARMACEUTICALS	Amlodipine Besylate 5 mg & Atenolol 50 mg Tablet	Uniformity of Weight	STP/TB26/025, ISSUE DT:13/09/2020
13	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Average weight	STP/T120/024, ISSUE DT:14/12/2020
14	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Uniformity of weight	STP/T120/024, ISSUE DT:14/12/2020
15	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Assay	STP/T120/024, ISSUE DT:14/12/2020
16	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Description	STP/T120/024, ISSUE DT:14/12/2020
17	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Disintegration test	STP/T120/024, ISSUE DT:14/12/2020
18	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Identification	STP/T120/024, ISSUE DT:14/12/2020

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 2 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
19	CHEMICAL- DRUGS & PHARMACEUTICALS	Atenolol 50 mg IP tablet	Related substances	STP/T120/024, ISSUE DT:14/12/2020
20	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Assay (By HPLC)	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
21	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Description	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
22	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Heavy Metals	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
23	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Identification	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
24	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Related Substances (By HPLC)	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
25	CHEMICAL- DRUGS & PHARMACEUTICALS	ATORVASTATIN CALCIUM	Solubility	STP/RM/PRA0017/016, ISSUE DT:06/06/2019
26	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Average weight	STP/ATE/359, ISSUE DT:07/09/2020
27	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Description	STP/ATE/359, ISSUE DT:07/09/2020
28	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Disintegration time	STP/ATE/359, ISSUE DT:07/09/2020
29	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Dissolution (By Liquid chromatography)	STP/ATE/359, ISSUE DT:07/09/2020
30	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Identification(By IR)	STP/ATE/359, ISSUE DT:07/09/2020
31	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Related substances By Liquid chromatography Any single impurity	STP/ATE/359, ISSUE DT:07/09/2020
32	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Related substances By Liquid chromatography Total impurity	STP/ATE/359, ISSUE DT:07/09/2020
33	CHEMICAL- DRUGS & PHARMACEUTICALS	Atorvastatin Tablet	Uniformity of weight	STP/ATE/359, ISSUE DT:07/09/2020
34	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography cis-cis-isomer (Shelf Life)	STP/ATK/609, Issue Date: 11/04/2020
35	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography cis-trans-isomer (Release)	STP/ATK/609, Issue Date: 11/04/2020

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 3 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
36	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography cis-trans-isomer (Shelf Life)	STP/ATK/609, Issue Date: 11/04/2020
37	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography Each ml contains Atracurium Besylate IP 10mg(Release)	STP/ATK/609, Issue Date: 11/04/2020
38	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography Each ml contains Atracurium Besylate IP 10mg(Shelf Life)	STP/ATK/609, Issue Date: 11/04/2020
39	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography trans-trans-isomer (Release)	STP/ATK/610, Issue Date:11/04/2020
40	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Assay Atracurium Besylate IP By Liquid Chromatography trans-trans-isomer (Shelf Life)	STP/ATK/609, Issue Date: 11/04/2020
41	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Description	STP/ATK/609, Issue Date: 11/04/2020
42	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Extractable Volume	STP/ATK/609, Issue Date: 11/04/2020
43	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Identification(By HPLC)	STP/ATK/609, Issue Date: 11/04/2020
44	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Particulate matter By visual inspection	STP/ATK/609, Issue Date: 11/04/2020
45	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography B. Sub of Cis & trans-isomers of hydroxy compound	STP/ATK/609, Issue Date: 11/04/2020
46	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography C. Laudanosine	STP/ATK/609, Issue Date: 11/04/2020
47	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography F. Any other unspecified impurity	STP/ATK/609, Issue Date: 11/04/2020
48	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography A. Acidic Compound	STP/ATK/609, Issue Date: 11/04/2020
49	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography E. Total impurities	STP/ATK/609, Issue Date: 11/04/2020

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 4 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
50	CHEMICAL- DRUGS & PHARMACEUTICALS	Atracurium Besylate Injection IP	Related substances By Liquid chromatography D Sum of Cis & trans-isomers of monoacrylate	STP/ATK/609, Issue Date: 11/04/2020
51	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Assay (By HPLC)Bupivacaine Hydrochloride 5.0mg/ml	STP/BUI/666, ISSUE DT:09/10/2019
52	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Assay(By Polarimeter) Dextrose 80.0mg/ml	STP/BUI/666, ISSUE DT:09/10/2019
53	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Description	STP/BUI/666,ISSUE DT:09/10/2019
54	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Extractable Volume average contents of the 3 containers	STP/BUI/666, ISSUE DT:09/10/2019
55	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Extractable Volume content of each individual container	STP/BUI/666, ISSUE DT:09/10/2019
56	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Extractable Volume maximum excess of individual container volume	STP/BUI/666, ISSUE DT:09/10/2019
57	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Identification(By HPLC)	STP/BUI/666, ISSUE DT:09/10/2019
58	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Identification(By IR)	STP/BUI/666, ISSUE DT:09/10/2019
59	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Particulate matter(by light obstruction method) Particles equal to or greater than 25 micron	STP/BUI/666, ISSUE DT:09/10/2019
60	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	Particulate matter(by light obstruction method)Particles equal to or greater than 10 micron	STP/BUI/666, , ISSUE DT:09/10/2019
61	CHEMICAL- DRUGS & PHARMACEUTICALS	Bupivacaine Hydrochloride(5.0mg/ml) with Dextrose Injection USP(80.0mg/ml)	pH	STP/BUI/666, , ISSUE DT:09/10/2019
62	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Assay(By Liquid chromatography)	STP/T104/015, ISSUE DT:30/01/2021
63	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Average weight	STP/T104/015, ISSUE DT:30/01/2021
64	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Disintegration time	STP/T104/015, ISSUE DT:30/01/2021
65	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Dissolution(By HPLC)	STP/T104/015, ISSUE DT:30/01/2021

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 5 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
66	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Friability	STP/T104/015, ISSUE DT:30/01/2021
67	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Identification(By IR)	STP/T104/015, ISSUE DT:30/01/2021
68	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Related substance In the chromatogram obtained with the test solution the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with reference solution	STP/T104/015, ISSUE DT:30/01/2021
69	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Uniformity Content	STP/T104/015, ISSUE DT:30/01/2021
70	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Uniformity of weight	STP/T104/015, ISSUE DT:30/01/2021
71	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Description	STP/T104/015, ISSUE DT:30/01/2021
72	CHEMICAL- DRUGS & PHARMACEUTICALS	Carvedilol Tablet IP	Related substance The sum of areas of all the secondary peak is not more than twice the area of the peak in the chromatogram obtained with solution	STP/T104/015, ISSUE DT:30/01/2021
73	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Assay of Cisatracurium besylate USP By Liquid Chromatography Each ml contains Cisatracurium besylate USP eq.to Cisatracurium 2mg(At time of release)	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
74	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Assay of Cisatracurium besylate USP By Liquid Chromatography Each ml contains Cisatracurium besylate USP eq.to Cisatracurium 2mg(Shelf Life)	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
75	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Clarity of solution	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
76	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Colour of solution	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019 :
77	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Description	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 6 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
78	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Extractable volume average contents of the 3 containers	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019:
79	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Extractable volume content of each individual container	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019:
80	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Identification(By Infra Red Spectroscopy)	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
81	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Identification(By Liquid Chromatography)	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
82	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) (R)-Laudanosine	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
83	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) Any individual unspecified Degradation product	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
84	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) Any individual unspecified Total Degradation products	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
85	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) cis-Monoacrylate	STP/CIS-REG(E)/535,ISSUE DT:03/12/2019
86	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) cis-Quaternary alcohol	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
87	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Organic Impurities (Related substances By Liquid Chromatography) cis-Quaternary acid	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
88	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Particulate matter By Light Obscuration method(Sub-Visible Particles)Particles equal to or greater than 10 microns	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
89	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	Particulate matter By Light Obscuration method(Sub-Visible Particles)Particles equal to or greater than 25 microns	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 7 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
90	CHEMICAL- DRUGS & PHARMACEUTICALS	Cisatracurium Besylate Injection USP	pH (at 25°C)	STP/CIS-REG(E)/535, ISSUE DT:03/12/2019
91	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Description	STP/T107/012, Issue Dt:13/12/2020
92	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Assay (By Liquid Chromatography) Clopidogrel Bisulphate equivalent to Clopidogrel	STP/T107/012, Issue Dt:13/12/2020
93	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Average weight	STP/T107/012 , Issue Dt:13/12/2020
94	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Disintegration time	STP/T107/012, Issue Dt:13/12/2020
95	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Identification (By HPLC)	STP/T107/012, Issue Dt:13/12/2020
96	CHEMICAL- DRUGS & PHARMACEUTICALS	Clopidogrel Bisulphate equivalent to Clopidogrel 75 mg tablet	Uniformity of weight	STP/T107/012, Issue Dt:13/12/2020
97	CHEMICAL- DRUGS & PHARMACEUTICALS	Dexmedetomidine Hydrochloride Injection USP	Description	STP/DMI/634,Issue Dt:22/06/2019
98	CHEMICAL- DRUGS & PHARMACEUTICALS	Dexmedetomidine Hydrochloride Injection USP	Related substances Any individual impurity	STP/DMI/634, Issue Dt:22/06/2019
99	CHEMICAL- DRUGS & PHARMACEUTICALS	Dexmedetomidine Hydrochloride Injection USP	Assay (By HPLC)Dexmedetomidine Hydrochloride USP eq. to Dexmedetomidine	STP/DMI/634, Issue Dt:22/06/2019
100	CHEMICAL- DRUGS & PHARMACEUTICALS	Dexmedetomidine Hydrochloride Injection USP	Identification	STP/DMI/634, Issue Dt:22/06/2019
101	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Assay Isoniazid Release Limit	STP/T113/054, Issue Dt:16/05/2019
102	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	2- Aminobutanol (By TLC)	STP/T113/054, Issue Dt:16/05/2019
103	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Assay Ethambutol Hydrochloride Shelf Life Limit	STP/T113/054, Issue Dt:16/05/2019
104	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Assay Ethambutol Hydrochloride Release Limit	STP/T113/054, Issue Dt:16/05/2019
105	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Assay Isoniazid Release Limit Shelf Life Limit	STP/T113/054 Issue Dt:16/05/2019
106	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Average weight	STP/T113/054, Issue Dt:16/05/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 8 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
107	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Description	STP/T113/054, Issue Dt:16/05/2019
108	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Disintegration time	STP/T113/054, Issue Dt:16/05/2019
109	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Dissolution	STP/T113/054, Issue Dt:16/05/2019
110	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Friability	STP/T113/054, Issue Dt:16/05/2019
111	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Identification(By HPLC)	STP/T113/054, Issue Dt:16/05/2019
112	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride 1000 mg and Isoniazid 300 mg Tablet	Uniformity of weight	STP/T113/054, Issue Dt:16/05/2019
113	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Uniformity of weight	STP/TB24/004, ISSUE DT:17/05/2019
114	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	2-Amino butanol	STP/TB24/004, ISSUE DT:17/05/2019
115	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Assay	STP/TB24/004, ISSUE DT:17/05/2019
116	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Average weight	STP/TB24/004, ISSUE DT:17/05/2019
117	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Description	STP/TB24/004, ISSUE DT:17/05/2019
118	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Disintigration time	STP/TB24/004, ISSUE DT:17/05/2019
119	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Dissolution	STP/TB24/004, ISSUE DT:17/05/2019
120	CHEMICAL- DRUGS & PHARMACEUTICALS	Ethambutol Hydrochloride Tablets IP	Identification	STP/TB24/004, ISSUE DT:17/05/2019
121	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Activity of Feracrylum	STP/ FEC/617, ISSUE DT:06/04/2019
122	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Assay	STP/ FEC/617, ISSUE DT:06/04/2019
123	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Content of Iron	STP/ FEC/617, ISSUE DT:06/04/2019
124	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Description	STP/ FEC/617, ISSUE DT:06/04/2019
125	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Identification of Feracrylum (By Chemical)	STP/ FEC/617, ISSUE DT:06/04/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 9 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
126	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	pH	STP/ FEC/617, ISSUE DT:06/04/2019
127	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1% Sterile Antiseptic Solution	Relative Viscosity at 25°C	STP/ FEC/617, ISSUE DT:06/04/2019
128	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Description	STP/TEI/619, ISSUE DT:27/07/2019
129	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Activity of Feracrylum	STP/TEI/619 , ISSUE DT:27/07/2019
130	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Average net fill volume	STP/TEI/619 , ISSUE DT:27/07/2019
131	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Identification	STP/TEI/619: ISSUE DT:27/07/2019
132	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	pH	STP/TEI/619, ISSUE DT:27/07/2019
133	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Unreacted Protein	STP/TEI/619, ISSUE DT:27/07/2019
134	CHEMICAL- DRUGS & PHARMACEUTICALS	Feracrylum 1.0%w/v Mouth Gargle	Weight per ml	STP/TEI/619, ISSUE DT:27/07/2019
135	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	Activity of Feracrylum	STP/GTS209/029,Issue Dt:28/02/2020
136	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	Average Net Content	STP/GTS209/029, Issue Dt:28/02/2020
137	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	Identification	STP/GTS209/029, Issue Dt:28/02/2020
138	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	pH	STP/GTS209/029, Issue Dt:28/02/2020
139	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	Unreacted Protein	STP/GTS209/029, Issue Dt:28/02/2020
140	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 1 %	Description	STP/GTS209/029, Issue Dt:28/02/2020
141	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 3%	Activity of Feracrylum	STP/CRP/299, Issue Dt:02/02/2019
142	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 3%	Average Net Content	STP/CRP/299, Issue Dt:02/02/2019
143	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 3%	Description	STP/CRP/299, Issue Dt:02/02/2019
144	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 3%	Identification	STP/CRP/299, Issue Dt:02/02/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 10 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
145	CHEMICAL- DRUGS & PHARMACEUTICALS	FERACRYLUM GEL 3%	pH (10 % w/v solution in water)	STP/CRP/299, Issue Dt:02/02/2019
146	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	Assay of Glycopyrolate IP(By HPLC) 0.5mg/5ml	STP/NEO/497,Issue Dt: 14/09/2019
147	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	Assay of Neostigmine Methylsulphate IP(By HPLC) 2.5mg/5ml	STP/NEO/497, Issue Dt: 14/09/2019
148	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	Description	STP/NEO/497, Issue Dt: 14/09/2019
149	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	Identification	STP/NEO/497, Issue Dt: 14/09/2019
150	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	Particulate Contamination Visible Particles	STP/NEO/497, Issue Dt: 14/09/2019
151	CHEMICAL- DRUGS & PHARMACEUTICALS	Glycopyrrolate and Neostigmine Methylsulphate Injection	pH (at 25 °C)	STP/NEO/497, Issue Dt: 14/09/2019
152	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Assay Benzethonium Chloride 0.01%w/v(By HPLC)	STP/KMI/346, Issue Dt:27/05/2019
153	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Assay Ketamine Hydrochloride IP 50mg/ml(By UV)	STP/KMI/346, Issue Dt:27/05/2019
154	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Identification(By UV)	STP/KMI/346, Issue Dt:27/05/2019
155	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Particulate matter(By visual inspection)	STP/KMI/346, Issue Dt:27/05/2019
156	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	pH	STP/KMI/346, Issue Dt:27/05/2019
157	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Related substances(By Liquid chromatography) Any Other Impurity	STP/KMI/346, Issue Dt:27/05/2019
158	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Related substances(By Liquid chromatography) Single Impurity	STP/KMI/346, Issue Dt:27/05/2019
159	CHEMICAL- DRUGS & PHARMACEUTICALS	Ketamine Hydrochloride Injection IP	Description	STP/KMI/346, Issue Dt:27/05/2019
160	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Assay Adrenaline IP 0.005mg	STP/TAD/367, Issue Dt:06/10/2020
161	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Assay Lignocaine HCL IP 21.3mg	STP/TAD/367, Issue Dt:06/10/2020
162	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Assay Methyl Paraben 1.0mg	STP/TAD/367, Issue Dt:06/10/2020

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 11 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
163	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Assay Sodium Chloride IP 6.0mg	STP/TAD/367, Issue Dt:06/10/2020
164	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Description	STP/TAD/367, Issue Dt:06/10/2020
165	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Identification(By CHEMICALLY)	STP/TAD/367, Issue Dt:06/10/2020
166	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	Particulate Matter	STP/TAD/367, Issue Dt:06/10/2020
167	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride and Adrenaline Injection IP	pH	STP/TAD/367, Issue Dt:06/10/2020
168	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Assay (Lignocaine Hydrochloride)	STP/THC/368, Issue Dt:07/12/2021
169	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Description	STP/THC/368, Issue Dt:07/12/2021
170	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Assay(Methyl Paraben IP)	STP/THC/368, Issue Dt:07/12/2021
171	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Assay(Sodium Chloride IP)	STP/THC/368, Issue Dt:07/12/2021
172	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Extractable Volume	STP/THC/368, Issue Dt:07/12/2021
173	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Identification(By CHEMICALLY)	STP/THC/368, Issue Dt:07/12/2021
174	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Particulate matter	STP/THC/368, Issue Dt:07/12/2021
175	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	pH	STP/THC/368 Issue Dt:07/12/2021
176	CHEMICAL- DRUGS & PHARMACEUTICALS	Lignocaine Hydrochloride injection IP	Related Substances(2,6-Dimethylaniline)	STP/THC/368, Issue Dt:07/12/2021
177	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Assay By HPLC Midazolam IP	STP/KBI/322, Issue Dt:09/03/2019
178	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Description	STP/KBI/322, Issue Dt:09/03/2019
179	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Extractable Volume	STP/KBI/322, Issue Dt:09/03/2019
180	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Particulate matter(By visual Inspection)	STP/KBI/322, Issue Dt:09/03/2019
181	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	pH	STP/KBI/322, Issue Dt:09/03/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 12 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
182	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Related Substances (By HPLC)	STP/KBI/322, Issue Dt:09/03/2019
183	CHEMICAL- DRUGS & PHARMACEUTICALS	Midazolam Injection IP	Assay By HPLC Benzyl alcohol IP	STP/KBI/322, Issue Dt:09/03/2019
184	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	3-Hydroxy trimethylanilinium methyl sulphate	STP/NTI/407, Issue Dt:26/11/2021
185	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	Assay Neostigmine Methylsulphate IP 0.5mg/ml	STP/NTI/407, Issue Dt:26/11/2021
186	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	Description	STP/NTI/407, Issue Dt:26/11/2021
187	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	Identification (By Chemically)	STP/NTI/407, Issue Dt:26/11/2021
188	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	Particulate matter(By visual)Visible Particles	STP/NTI/407, Issue Dt:26/11/2021
189	CHEMICAL- DRUGS & PHARMACEUTICALS	Neostigmine Methyl Sulphate Injection IP	pH	STP/NTI/407, Issue Dt:26/11/2021
190	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Assay Nor Adrenaline Bitartrate IP(At time of release)	STP/NAD/338, Issue Dt: 19/03/2020
191	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Assay Nor Adrenaline Bitartrate IP(Shelf Life)	STP/NAD/338, Issue Dt: 19/03/2020
192	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Description	STP/NAD/338, Issue Dt: 19/03/2020
193	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Extractable volume	STP/NAD/338, Issue Dt: 19/03/2020
194	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Identification (By Chemically)	STP/NAD/338, Issue Dt: 19/03/2020
195	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	Particulate matter	STP/NAD/338, Issue Dt: 19/03/2020
196	CHEMICAL- DRUGS & PHARMACEUTICALS	Noradrenaline Bitartrate Injection IP	pH	STP/NAD/338, Issue Dt: 19/03/2020
197	CHEMICAL- DRUGS & PHARMACEUTICALS	Palonosetron Hydrochloride Injection(in house)	Assay Palonosetron HCL 0.250mg	STP/THA/171, Issue Dt: 08/02/2019
198	CHEMICAL- DRUGS & PHARMACEUTICALS	Palonosetron Hydrochloride Injection(in house)	Description	STP/THA/171, Issue Dt: 08/02/2019
199	CHEMICAL- DRUGS & PHARMACEUTICALS	Palonosetron Hydrochloride Injection(in house)	Identification	STP/THA/171 , Issue Dt: 08/02/2019
200	CHEMICAL- DRUGS & PHARMACEUTICALS	Palonosetron Hydrochloride Injection(in house)	Particulate Matter	STP/THA/171 , Issue Dt: 08/02/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 13 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
201	CHEMICAL- DRUGS & PHARMACEUTICALS	Palonosetron Hydrochloride Injection(in house)	pH value	STP/THA/171, Issue Dt: 08/02/2019
202	CHEMICAL- DRUGS & PHARMACEUTICALS	Ph	Tramadol Hydrochloride Injection	STP/TEM/516, Issue Dt:28/01/2020
203	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Assay	STP/TT26/075, Issue Dt: 20/04/2020
204	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Average weight	STP/TT26/075, Issue Dt: 20/04/2020
205	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Description	STP/TT26/075, Issue Dt: 20/04/2020
206	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Disintigration time	STP/TT26/075, Issue Dt: 20/04/2020
207	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Identification	STP/TT26/075, Issue Dt: 20/04/2020
208	CHEMICAL- DRUGS & PHARMACEUTICALS	Pyrazinamide tablet	Uniformity of weight	STP/TT26/075, Issue Dt: 20/04/2020
209	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Assay Ropivacaine HCL IP 2.0mg	STP/ ROA/659, Issue Dt: 15/10/2020
210	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Assay Sodium Chloride IP 8.6mg	STP/ ROA/659,Issue Dt: 15/10/2020
211	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Description	STP/ ROA/659, Issue Dt: 15/10/2020
212	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Enantiomeric purity	STP/ ROA/659, Issue Dt: 15/10/2020
213	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Identification (By Chemically)	STP/ ROA/659, Issue Dt: 15/10/2020
214	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Limit of NMT 0.01 % 2,6-Dimethylaniline Hydrochloride(Ropivacain e related compound A Base)	STP/ ROA/659, Issue Dt: 15/10/2020
215	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	Particulate Matter	STP/ ROA/659, Issue Dt: 15/10/2020
216	CHEMICAL- DRUGS & PHARMACEUTICALS	Ropivacaine Hydrochloride injection IP	pH	STP/ ROA/659, Issue Dt: 15/10/2020
217	CHEMICAL- DRUGS & PHARMACEUTICALS	SEPGARD AR GEL	Assay Centbucridine	STP/TG01/031, Issue Dt: 25/07/2019
218	CHEMICAL- DRUGS & PHARMACEUTICALS	SEPGARD AR GEL	Assay Feracrylum	STP/TG01/031, Issue Dt: 25/07/2019

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 14 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
219	CHEMICAL- DRUGS & PHARMACEUTICALS	SEPGARD AR GEL	Description	STP/TG01/031, Issue Dt: 25/07/2019
220	CHEMICAL- DRUGS & PHARMACEUTICALS	SEPGARD AR GEL	Identification	STP/TG01/031, Issue Dt: 25/07/2019
221	CHEMICAL- DRUGS & PHARMACEUTICALS	SEPGARD AR GEL	pH	STP/TG01/031, Issue Dt: 25/07/2019
222	CHEMICAL- DRUGS & PHARMACEUTICALS	Sterile Noradrenaline Concentrate IP	Assay Noradrenaline Bitartrate IP 1.0mg	STP/NEI/342, Issue Dt: 07/04/2020
223	CHEMICAL- DRUGS & PHARMACEUTICALS	Sterile Noradrenaline Concentrate IP	Description	STP/NEI/342, Issue Dt: 07/04/2020
224	CHEMICAL- DRUGS & PHARMACEUTICALS	Sterile Noradrenaline Concentrate IP	Identification(By Chemically)	STP/NEI/342, Issue Dt: 07/04/2020
225	CHEMICAL- DRUGS & PHARMACEUTICALS	Sterile Noradrenaline Concentrate IP	Particulate matter	STP/NEI/342, Issue Dt: 07/04/2020
226	CHEMICAL- DRUGS & PHARMACEUTICALS	Sterile Noradrenaline Concentrate IP	pH	STP/NEI/342, Issue Dt: 07/04/2020
227	CHEMICAL- DRUGS & PHARMACEUTICALS	STP/DMI/634	pH	STP/DMI/634, Issue Dt: 22/06/2019
228	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	Assay of Succinylcholine Chloride (By Titration)	STP/SUC/514, Issue Dt: 15/06/2020
229	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	Description	STP/SUC/514, Issue Dt: 15/06/2020
230	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	Hydrolysis products	STP/SUC/514, Issue Dt: 15/06/2020
231	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	Identification (By chemically)	STP/SUC/514, Issue Dt: 15/06/2020
232	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	Particulate contamination Visible Particles	STP/SUC/514, Issue Dt: 15/06/2020
233	CHEMICAL- DRUGS & PHARMACEUTICALS	Succinylcholine Injection IP	pH (at 25 ºC)	STP/SUC/514, Issue Dt: 15/06/2020
234	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Assay (for Diclofenac Sodium)	STP/TDD/240, Issue Dt:21/12/2020
235	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Assay(for Tolperisone HCl)	STP/TDD/240, Issue Dt:21/12/2020
236	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Average weight	STP/TDD/240, Issue Dt:21/12/2020
237	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Description	STP/TDD/240, Issue Dt:21/12/2020

SCOPE OF ACCREDITATION

Laboratory Name : THEMIS MEDICARE LIMITED, SECTOR -6A, PLOT NO.16, 17, & 18, IIE, SIDCUL, HARIDWAR, UTTARAKHAND, INDIA

Accreditation Standard ISO/IEC 17025:2017

Certificate Number TC-10107 **Page No** 15 of 15

Validity 01/12/2021 to 30/11/2023 **Last Amended on** -

S.No	Discipline / Group	Materials or Products tested	Component, parameter or characteristic tested / Specific Test Performed / Tests or type of tests performed	Test Method Specification against which tests are performed and / or the techniques / equipment used
238	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Disintegration time	STP/TDD/240, Issue Dt:21/12/2020
239	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Identification	STP/TDD/240, Issue Dt:21/12/2020
240	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone HCl 150mg & Diclofenac 50 mg Tablets	Uniformity of weight	STP/TDD/240, Issue Dt:21/12/2020:
241	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Assay	STP/TPD/127, Issue Dt: 02/11/2019
242	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Identification	STP/TPD/127, Issue Dt: 02/11/2019
243	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Average weight	STP/TPD/127, Issue Dt: 02/11/2019
244	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Disintegration test	STP/TPD/127, Issue Dt: 02/11/2019
245	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Uniformity of weight	STP/TPD/127, Issue Dt: 02/11/2019
246	CHEMICAL- DRUGS & PHARMACEUTICALS	Tolperisone Hydrochloride Tablets	Description	STP/TPD/127, Issue Dt: 02/11/2019
247	CHEMICAL- DRUGS & PHARMACEUTICALS	Tramadol Hydrochloride Injection	Assay	STP/TEM/516Issue Dt:28/01/2020
248	CHEMICAL- DRUGS & PHARMACEUTICALS	Tramadol Hydrochloride Injection	Description	STP/TEM/516, Issue Dt:28/01/2020
249	CHEMICAL- DRUGS & PHARMACEUTICALS	Tramadol Hydrochloride Injection	Identification	STP/TEM/516, Issue Dt:28/01/2020
250	CHEMICAL- DRUGS & PHARMACEUTICALS	Tramadol Hydrochloride Injection	Particulate Matter Visible Particles	STP/TEM/516, Issue Dt:28/01/2020
251	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Assay	STP/TDN/605, Issue Dt: 12/01/2019
252	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Average weight	STP/TDN/605, Issue Dt: 12/01/2019
253	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Description	STP/TDN/605, Issue Dt: 12/01/2019
254	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Disintegration test	STP/TDN/605, Issue Dt: 12/01/2019
255	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Identification	STP/TDN/605, Issue Dt: 12/01/2019
256	CHEMICAL- DRUGS & PHARMACEUTICALS	Trimetazidine Dihydrochloride Tablet	Uniformity of weight	STP/TDN/605, Issue Dt: 12/01/2019